Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cobimetinib - Genentech

Drug Profile

Cobimetinib - Genentech

Alternative Names: Cobimetinib fumarate; Cotellic; GDC-0973; RG-7421; RO 5514041; XL-518

Latest Information Update: 28 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Exelixis
  • Developer Bristol-Myers Squibb; Exelixis; Genentech; M. D. Anderson Cancer Center; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; Roche; University Hospital Tubingen
  • Class Antineoplastics; Azetidines; Fluorobenzenes; Iodobenzenes; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Phase III Colorectal cancer
  • Phase II Brain metastases; Breast cancer; Head and neck cancer; Histiocytosis; Renal cell carcinoma; Urogenital cancer
  • Phase I/II Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Phase I Fallopian tube cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 28 Nov 2019 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Inoperable/Unresectable, Late-stage disease) in USA (PO, Tablet)
  • 25 Jul 2019 Roche terminates phase III development in Malignant melanoma (Combination therapy, First-line therapy, Inoperable/Unresectable, Metastatic disease) before July 2019 (Roche pipeline, July 2019)
  • 25 Jun 2019 Roche completes a phase Ib trial for Colorectal cancer (Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater, Combination therapy) in USA and Spain (PO) (NCT02876224)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top